Improve patient management
Deepen understanding of genetic causes
Recent, rapid advancements in the understanding of genetic causes of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) paved the way for development of gene-targeted genetic therapies tailored toward individual patients.1 Genetic testing to evaluate for the neurodegenerative conditions is an increasingly vital component in the diagnosis and management of individuals affected by ALS or FTD.
Mayo Clinic Laboratories’ FTD and ALS evaluations include both targeted panels and single gene evaluations to confirm and clarify diagnosis. Using next-generation sequencing, our assays provide improved coverage, offering increased sensitivity at above 99% for single nucleotide variants, above 94% for deletions/insertions less than 40 base pairs (bp), and above 95% for deletions up to 75 bp and insertions up to 47 bp.
C90RF | C9orf72 Hexanucleotide Repeat, Molecular Analysis, Varies
AFTDP | Inherited Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Gene Panel, Varies
SOD1Z | SOD1 Gene, Full Gene Analysis, Varies